Chromosomal microarray in prenatal diagnosis - replacing traditional karyotyping by Winther, Alise Marie
i 
Faculty of Health Science 
Chromosomal microarray in prenatal diagnosis 
– replacing traditional karyotyping
Alise Marie Winther, MK-14 




The purpose of this thesis was to learn about chromosomal microarray (CMA) and its role in 
invasive prenatal testing and evaluate the findings in a selected North Norwegian population, 
all in the light of other published studies. In recent years, several papers concerning the 
developments in both non-invasive and invasive testing has been published. CMA offers higher 
resolution and detection of smaller copy number variations (CNVs) compared to conventional 
karyotyping (G-band analysis) but does not reveal all genomic aberrations. Fetal karyotyping 
was replaced by CMA in the Department of Medical Genetics at University hospital of North 
Norway (UNN) in 2017. In this study we compared karyotyping results (obtained from 
December 2015 until August 2017) with CMA results (obtained from August 2017 to December 
2018). To my knowledge, this has not been investigated in a Norwegian population.  
Ragnhild Glad helped define variables before data collection. Data was collected from the 
patients’ medical records with help from Mona Nystad. I ran the statistical analyses and wrote 
the thesis with guidance from both supervisors. 
I would like to thank my supervisors Mona Nystad and Ragnhild Glad for excellent guidance 
and support throughout the process. They are both great role models and inspire me to become 
a better medical physician for my patients. I would also like to thank the Department of Medical 
Genetics for giving me the opportunity to learn more about the advancing technology in genetic 
testing and the clinical challenges that prenatal diagnosis raises. At last I have to thank my 
boyfriend Bjørn-Eivind Kirsebom for support, love and amazing cooking in a period of 
intensive work. 
Tromsø 02.06.19 
Alise Marie Winther 
iii 
Table of Contents 
Preface ....................................................................................................................................... ii 
Abstract ..................................................................................................................................... v 
Abbreviations ........................................................................................................................... vi 
1 Background/ Introduction ................................................................................................ 1 
1.1 Norwegian biotechnology law and indication of prenatal diagnosis .......................... 1 
1.2 Ultrasound in prenatal diagnosis ................................................................................ 2 
1.3 Biochemical serum markers in prenatal diagnosis ..................................................... 3 
1.4 Genetic testing in prenatal diagnosis .......................................................................... 4 
1.4.1 Quantitative fluorescens polymerase chain reaction ................................................ 5 
1.4.2 Karyotyping ............................................................................................................. 5 
1.5 Chromosomal Microarray analysis in prenatal diagnosis .......................................... 5 
1.5.1 The difference between aCGH and SNP method .................................................... 6 
1.5.2 Indications of performing CMA ............................................................................ 10 
1.5.3 Detection rates of CMA in published literature ..................................................... 10 
1.6 Genetic counselling and ethical considerations in prenatal genomic testing ........... 11 
1.7 Aim of the study ......................................................................................................... 11 
2 Material and Methods .................................................................................................... 12 
2.1 Study design and data ................................................................................................ 12 
2.2 Karyotyping ............................................................................................................... 12 
2.3 Quantitative fluorescence PCR analysis ................................................................... 12 
2.4 CMA analysis ............................................................................................................. 12 
2.5 Nomenclature of variants .......................................................................................... 13 
2.6 Classifications and interpretation of CMA results .................................................... 13 
2.6.1 Benign and normal results ..................................................................................... 14 
2.6.2 Uncertain results .................................................................................................... 14 
iv 
2.6.3 Pathogenic results .................................................................................................. 14 
2.7 Population of the study .............................................................................................. 15 
2.8 Definition of variables ............................................................................................... 15 
2.9 Data analysis ............................................................................................................. 15 
3 Results .............................................................................................................................. 16 
3.1 The Karyotyping group .............................................................................................. 16 
3.2 Genetic findings in the karyotype group .................................................................... 17 
3.3 The CMA group ......................................................................................................... 18 
3.4 Genetic findings in the CMA group ........................................................................... 20 
3.4.1 Ultrasound findings and CMA test results ............................................................. 21 
3.5 Comparing demographics and number of findings between groups ......................... 23 
4 Discussion ......................................................................................................................... 24 
4.1 Important findings ..................................................................................................... 24 
4.1.1 Genetic findings in the karyotyping group and the CMA group ........................... 24 
4.1.2 Abnormal copy number variants compared to ultrasound findings ....................... 25 
4.2 Results compared to relevant literature .................................................................... 25 
4.3 Benefits and Strengths of the study ............................................................................ 26 
4.3.1 First Norwegian data published ............................................................................. 26 
4.3.2 Limited knowledge of prenatal phenotype ............................................................ 26 
4.3.3 Reporting of genetic information ........................................................................... 27 
4.4 Limitations and weakness of the study ...................................................................... 27 
4.5 Future perspectives of prenatal diagnosis ................................................................. 28 
5 Conclusion ....................................................................................................................... 29 
6 GRADE-evaluation ......................................................................................................... 30 
7 References ........................................................................................................................ 35 
v 
Abstract 
Background: In prenatal diagnosis, chromosomal microarray analysis (CMA) has not yet 
fully replaced conventional karyotyping. As CMA is able to detect smaller genomic 
imbalances compared to conventional karyotyping, it has become the first-tier test in 
pregnancies with ultrasound abnormalities.  
Objectives/aims: The aim of the study was to learn about CMA and its appliance in invasive 
prenatal testing and evaluate the findings in a selected pregnant population. We intended to 
discuss diagnostic yield using quantitative fluorescence polymerase chain reaction (QF-PCR) 
prior to CMA instead of QF-PCR and karyotyping.  
Methods: Data was collected at the University hospital of North Norway Department of 
Medical Genetics. The sample comprised 85 women aged 19 – 45 years (M=33.12, SD=6.6). 
Between December 2015 and august 2017, QF-PCR and karyotyping were performed in n=43 
fetuses from women aged 19 - 44 (M=34.3, SD=6.4). Between September 2017 and 
December 2018 QF-PCR and CMA were performed in 41 fetuses from women aged 19 – 45 
years (M=31.8, SD=6.7).  
Results: In the Karyotyping group, 18.6 % of the fetuses had a results of clinical importance 
(trisomy, monosomy and mosaic trisomy). In the CMA group, 24.3 % of the patients had a 
copy number variant (CNV) which were either pathogenic (class 5), likely pathogenic (class 
4) or a variant of uncertain significance (VOUS). Only a small fraction (4,8%) of the CNVs in
the CMA group were classified as class 4-5 and reported to the patients. Only one of these 
CNVs would have been detected by karyotyping and only one was detected by QF-PCR. 
Conclusion: As the purpose of this thesis was to learn about CMA and its role in invasive 
prenatal testing and evaluate the findings; we found CNVs that would not have been detected 
using karyotyping alone in the CMA group. Supporting the literature describing benefits for 
changing the invasive testing methods. However, findings of uncertain clinical significance 
challenge the genetic counselling. Therefore, a national collection of data concerning prenatal 






aCGH – array comparative genomic hybridization 
CMA – chromosomal microarray analysis 
CNV – copy number variant 
CUB – combined ultrasound and blood test  
DD – developmental delay 
DNA – deoxyribonucleic acid 
ID – intellectual disability 
LCSH – long continuously stretches of homozygosity 
LOH – loss of heterozygosity  
NGS - next-generation sequencing 
NT – nuclear translucency 
OMIM – Online Mendelian Inheritance in Man  
QF-PCR – Quantitative fluorescent Polymerase Chain Reaction 
PAPP-A – Pregnancy associated plasma protein A 
SL – susceptibility loci 
SNP – single nucleotide polymorphism  
TAU – transabdominal ultrasound 
TVU – transvaginal ultrasound  
T21 – trisomy 21 
T18 – trisomy 18 
T13 – trisomy 13 
UPD - uniparental disomy  
VOUS – variant of uncertain significance 
WES - whole exome sequencing 





1 Background/ Introduction 
1.1 Norwegian biotechnology law and indication of prenatal diagnosis 
The biotechnology law in Norway defines prenatal diagnosis as investigation of the fetus, fetal 
cells, or the mother, with the intention to gather information of the fetus genetic characteristics. 
Ultrasound is therefore seen as part of prenatal diagnosis only if its performed with the intention 
of detecting or excluding disease or aberrations in fetal development (2). Approximately 4 % 
of Norwegian children are born with organ anomalies (3). According to the national birth 
register in Norway, in 2017 there were 219 of 57 930 fetuses that had a chromosomal 
abnormality, which accounted for about 0.4 % (3). Some of these may be caused by rare 
conditions or syndromes due to underlying aberrations in the DNA of the fetus. The aim of 
prenatal diagnosis is to identify these pregnancies in order to map out the risk factors, foresee 
and consider prognosis, and find the best way to aid the couple or mother throughout the 
pregnancy, during labor and after birth. This includes treatments when possible. In Norway all 
women are offered ultrasound scanning from gestational week 17 – 19 (2). First trimester 
ultrasound scan is considered prenatal diagnostics in Norway and therefore only offered 
patients with known risk factors such as advanced age, exposure to teratogens, or having known 
genetic diseases or risks in their family. Other indications for a first trimester scan may be 
challenging circumstances in life that complicate having a child with great disability. Anxiety 
alone is not an indication for prenatal diagnosis, but may be an indication of a first trimester 
ultrasound examination. For this reasons, today only a small group (about 11 %) of Norwegian 
women are given the choice of prenatal screening testing (2). The main indication for testing in 
2017 was maternal age above 38 years (48 %) and abnormal ultrasound findings counting for 




Figure 1 Schematic representation of the order of the screening tests. Indications for invasive testing are depicted. The 
CUB-test are initially offered to patients with known risk factors as advanced maternal age, exposure to teratogens ect. The 
screening is performed in the first trimester. 
In prenatal diagnosis both non-invasive and invasive techniques are used. The non-invasive 
techniques are a combination of ultrasound biometrics and biochemical serum markers. 
Combined Ultrasound Blood (CUB)-test consist of the biochemical serum markers pregnancy-
associated plasma protein A (PAPP-A) and free β-human choriogonadotropin (β-hCG) in 
combination with ultrasound biometrics. Together these values calculate a score of risk. In 
addition, a maternal blood test collecting cell free fetal deoxyribonucleic acid (cffDNA) 
fragments known as a non-invasive prenatal test (NIPT) are offered. The test is used as 
screening and the high risk (differently defined) group is offered invasive testing (figure 1). 
Invasive tests involves gathering material from the placenta or amniocentesis, and constitutes 
a 2 % risk of pregnancy loss (5).  
1.2 Ultrasound in prenatal diagnosis 
While ultrasound does not provide genetic information about the fetus (5), it is recognized as a 
safe screening tool for the detection of fetal malformations and useful in prenatal phenotyping. 
The technique is non-invasive, and there is no known associated risk of miscarriage. Early in 
pregnancy it is preferable to use transvaginal ultrasound (TVU) for examinations of the fetus, 
while transabdominal ultrasound (TAU) scanning is more commonly used in second trimester. 
The limitations attached to ultrasound screening are important to note, owing in part to the 
access of visibility which may be impeded by maternal high body mass index or how the fetus 
is situated in the uterus. In addition, one cannot be certain that an observed abnormality is 
isolated from ultrasound examinations, no matter how experienced the operator is (6). 
CUB-test
High risk of 
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Abnormalities may also develop with time and therefore repeated examinations may be 
required for making an accurate diagnosis. The detection rate of anomalies found in ultrasound 
scans depend on several factors. The type of anomaly may present different detection rates 
according to the nature of the specific anomaly. Some structural abnormalities are easy to 
diagnose due to their prominent visibility; others are more difficult. Garne et al., 2010 showed 
that detection rate of a hypoplastic left heart was 65 % and gastroschisis 85 % (7, 8). Timing is 
another important factor, because gestational week of pregnancy determine what to investigate 
during the ultrasound examination (9). Some “soft markers”, like the lack of nasal bone or 
nuchal translucency (NT) thickness (10), should be considered in the first trimester, while other 
signs are rarely visible before the second trimester. Microcephaly and agenesia /hypoplasia of 
the corpus callosum are hardly ever detectable in the first trimester, while reference values for 
NT is limited to examinations from week 10 to 14 (11). Nuchal fold increases with gestational 
age at about 17 % and disappears when the subcutaneous tissue becomes more echogenic. 
Consequently, a normal first trimester scan does not exclude the possibility of abnormal 
findings in the second trimester, and parents should therefore be carefully counselled about the 
limitations of anatomy assessment in the first trimester (6). First trimester screening studies 
using TVU/TAU scanning for fetal abnormalities, show a detection rate in the range of 31 – 65 
% in low risk population and 54 – 74 % in high risk pregnancies (8). The detection rate of 
combining both first, and second trimester scan, increase the detection rate of anomalies to as 
high as 97.4 % (8). 
1.3 Biochemical serum markers in prenatal diagnosis 
Serum markers that may be measured in prenatal diagnosis are PAPP-A, β-hCG, estriol, α-
fetalprotein and NIPT. The measured concentrations of either PAPP-A or free β-hCG are 
converted into the multiples of median (MoM) appropriate to the gestational age of each 
pregnancy (12). PAPPA-A is a large glycoprotein produced by the placental 
syncytiotrophoblast and decidua. In a healthy pregnancy the maternal serum PAPP-A increase 
exponentially (11). Its function is thought to be multiple as it plays a role in several mechanisms 
concerning prevention of recognition of the fetus by the maternal immune system, matrix 
mineralization, and angiogenesis. If the value of the PAPP-A protein is low, <0.4 MoM, it may 
indicate a poor early placentation, which in turn may lead to other complications such as IUGR, 
preeclampsia or still birth. (13). The concentration of PAPP-A may be different in fetuses with 
genetic conditions, but is a poor predictor alone, since it has a high false positive rate. We 
therefore use it in combination with β-hCG values and NT measurements. β-hCG is a 
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glycoprotein hormone normally found in blood and urine only during pregnancy. Its function 
is to initiate and maintain pregnancy by influencing and mediate multiple placental, uterine and 
fetal functions. In a healthy pregnancy the value drops after an initial increase between week 
10 to 14. A value above 1.5 MoM is considered to be associated with T21. One recent study in 
Poland showed that free β-hCG MoM over 1.5 was seen in 85% of cases with T21, but only 53 
% had PAPP-A MoM below 0.5. In most of the cases with high β-hCG and normal PAPP-A 
value, the NT measurement was increased. This shows that combining ultrasound soft markers, 
like NT, with serum-markers, enhance the probability of detecting specific chromosomal 
abnormalities as trisomies (11, 13) and certain other genetic syndromes (14-17). Sensitivity for 
detection of T21 by combining first trimester scan, double test (free β-hCG and PAPP-A), 
maternal age over 35 years together with NT varies from 85 – 95 %, and is possible to 
implement from weeks 8 – 14 (10). Also, it is possible to detect short fetal DNA sequences 
released from the placentas apoptotic syntiotrophoblast cells in maternal blood. This method is 
called NIPT, as mentioned earlier, and is an expensive test. Test result using NIPT may be 
difficult to interpret in conditions like high maternal body mass index, twin pregnancy, or 
mosaicism. The NIPT test is therefore not a diagnostic test, but a screening test with improved 
quality. One study from the United States (US) showed a high positive predictive value overall 
(87.2 %) concerning sex-chromosomal aneuploidies, microdeletions, and trisomy 13, 18 and 
21 (18). 
1.4 Genetic testing in prenatal diagnosis 
There are different methods of performing genomic testing. Array comparative genomic 
hybridization analysis (aCGH) and single nucleotide polymorphism (SNP)-array are both used 
for detection of deletions and duplications among other gross chromosome abnormalities. 
While gene mutations are detected through analysis by next generation sequence analysis 
(NGS), which enables many genes to be sequenced together in a single test. Genome exons 
represent 1 – 2 %, and consist of protein coding genes. Mutations in exons may therefore be of 
interest concerning genetic disorders. Gene-panels, all exons (exomes or whole exome 
sequencing (WES)) or whole genome sequencing (WGS) approaches may be used. However, 
in the prenatal setting, Norway performs NGS only where the fetus has ultrasound findings like 
with e.g. skeletal dysplasia where NGS-panels with skeletal gene panels are run on prenatal 
samples.  
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1.4.1 Quantitative fluorescens polymerase chain reaction 
Quantitative fluorescens polymerase chain reaction (QF-PCR) is used for detection of specific 
aneuploidies in prenatal diagnosis. It is performed from the amniocentesis or CVS and gives 
the patient a rapid aneuploidy detection. The test detects chromosome copy number by 
amplification techniques of the most common aneuploidies trisomy 13, -18, -21 and sex 
chromosomes. Also, QF-PCR may be useful if time is an issue, e.g. if the mother is 
developing complications during pregnancy, like preeclampsia. 
1.4.2 Karyotyping 
Conventional karyotyping (G-banding) is a method used to investigate fetal cells obtained from 
invasive procedures. It is a visual technique where chromosomes are isolated, labelled by 
Giemsa stain and characterized in the microscope. Homologous chromosomes are paired 
according to size, banding patterns and centromere location to reveal the structural features of 
each chromosome (10).  The process of the karyotyping method depends on dividing cells for 
isolation of metaphase chromosomes. Karyotyping is limited by the resolution of the light 
microscope and cannot detect duplications or deletions less than 5 megabases (Mb) (10-12) in 
size and also by the subjective evaluation of the technician. The fact that karyotyping also 
depends on cultured cells to grow, makes it a time consuming method (1) as well as labour 
intensive, with the technician being able to handle only about 250 samples per year (11). The 
benefits of G-banding is that it may detect balanced translocations, which provides important 
information regarding recurrence risk in future pregnancies. It may also identify mosaicism. 
1.5 Chromosomal Microarray analysis in prenatal diagnosis 
Chromosomal microarray analysis (CMA) is a form of molecular cytogenomic technique where 
we look at the DNA of the fetus in a submicroscopic level, enabling detection of aberrations as 
low as 0.7 kilobases (Kb) (19, 20). This form of higher resolution is able to detect copy number 
variants (CNVs) in the genome in form of deletions (one copy) and duplications (three copies 
or more) from thousand base pairs to several Mb in length (21-24). These changes are less 
correlated with maternal age (25, 26). Fetal material suitable for CMA are chorionic villi, 
amniotic fluid, fetal blood, fetal pleural effusion or fetal urine. There are two main types of 
CMA currently performed: array comparative genomic hybridization (aCGH) and single 
nucleotide polymorphism (SNP) microarray (1). The benefits of using CMA is a high sensitivity 
value, and a faster turn-around time due to the possibility of using uncultured, or even non-
dividing material. CMA can also detect early onset disorders such as Duchenne muscular 
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dystrophy, and mosaics down to about 30 % (27, 28). Balanced chromosomal aberrations and 
localization of extra chromosomal material, will not be detected by CMA. Neither can all small 
CNVs and point mutations be detected. 
1.5.1 The difference between aCGH and SNP method 
Array comparative genomic hybridization (aCGH) analysis compares the patient’s DNA-
sample to a normal reference DNA-sample reference. Both samples are fluorescently labelled 
with two different colors and hybridized to a chip containing the genome (figure 3). By 
measuring the fluorescent signals with a scanner, a plot generates from this hybridized 
microarray where the ratio between the sample and the reference DNA can be seen. An excess 
will imply a duplication, whereas a deficiency of test DNA will imply a deletion. The 
disadvantage of the aCGH is that it cannot identify triploidies because the chromosome which 
is redundant is simultaneously increased. The SNP array method do not use a comparative 
reference DNA sample, but instead determine the genotype of the highly polymorphic regions 
of the DNA between individuals, which are called different SNPs (figure 2 and 4). 
  
Figure 2 Schematic representation of different SNPs in different individuals. SNP are a type of polymorphism in the 
genome involving variation of a single base pair and can be correlated with risk of disease in regions of interest in the genome. 
Here we see different individuals with their chromosome 2 homologs and how they differ in single base pair. Courtesy: National 





Figure 3 Array CGH analysis (1).  
(A) After amplification, digestion and labeling processes the reference DNA and test DNA both hybridize to the array. A scanner 
generates a plot of the fluorescence signals which determinate the ratio of reference to test DNA at each fragment on the array. Red shows 




These areas of polymorphisms must occur with an allele frequency of at least 1 % in the 
population to be defined as SNPs. These germline point mutations, are naturally and statically 
occurring in the course of evolution (19). In a single human DNA there will be around 4 to 5 
million SNPs, occurring almost once in every 1000 nucleotide on average. Most of the time a 
single SNP gives us sparse information about a person. In order to find an association between 
SNPs and disease, one has to look at multiple SNPs across the DNA. Each combination of SNPs 
is called a haplotype. Of all the possible haplotypes there are usually only a few of the 
combinations that actually exist in the population, and all humans have a pair, one from each 
parent. The haplotype pair can be seen as an individual’s own SNP profile, as shown in figure 
2. The principles of Affymetrix SNP array technology are shown in figure 4. First DNA is 
digested to fragments of varying lengths by restriction enzymes. Subsequently, the fragments 
of the DNA are ligated to adapters to enable a one-primer PCR to produce even smaller 
fragments of selected size (200-1100 bp) (19). After the fragments are labeled with 
fluorochrome and hybridized to the microarray, the DNA fragments from the sample can find 
the probe containing its perfect match of nucleotides forming a unique haplotype, or a SNP 
profile. There are two different types of probes analyzing test DNA; one which identifies SNPs 
and the other identifies CNVs (up to eight copies). Unlike aCGH the SNP arrays are therefore 
able to identify triploidies, homozygosity areas in the genome, or even areas of uniparental 
disomi (UPD) (1, 19). In the case of UPD, the fetus inherits both chromosomes from either of 
the parents (having a chromosome of two identical haplotypes/SNP profiles), instead of getting 
one from each, which may lead to known syndromes like Angelman or Prader-Willi.  
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Figure 4 Principle of Affymetrix SNP array technology. Restriction enzymes digest test DNA to fragments of varying 
lengths, and they are next subjected to ligation to adapters. PCR primers then produce fragments of selected size which are 
labelled with fluorocrome so that the DNA fragments can be hybridized on the array. In the array the SNPs in the test DNA 
find their complementary match in the probes. After washing, the hybridized array is then scanned by a laser. The raw data can 
then be calculated into intensity of fluorescent signals in form of the DNA copy number and determination of SNP alleles to 
form a genotype (19). 
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1.5.2 Indications of performing CMA 
At the University hospital of Northern Norway, CMA is used when non-invasive screening 
procedures indicates invasive testing. Indications for invasive testing are structural 
malformations (also isolated malformations) detected by ultrasound scans, known risk of 
genetic disease from family history, fetal intra uterine growth restriction (IUGR), or positive 
risk assessment results from CUB-testing or NIPT.  
1.5.3 Detection rates of CMA in published literature 
The prevalence of CNVs using CMA, and its relation to specific ultrasound anomalies varies 
between studies. The phenotype links to CNVs are mostly studied in postnatal settings, which 
makes phenotyping in prenatal diagnosis challenging. The most common anomalies associated 
with CNVs occur in the cardiac, skeletal, urogenital, renal and central nervous system (CNS) 
(28). Stosic et al., 2017 summarized in a review article that CMA may detect CNVs with well-
defined clinical significance in up to 1.7% with a normal ultrasound and karyotype (30). If 
abnormalities are detected by ultrasound, the detection rate rises up to 6 % (1). However, the 
percentage is reduced to 5.6 % if the ultrasound finding is isolated. The lowest prevalence is 
shown for isolated NT (3.1 %), indicating that this is a soft sign with low specificity. Similarly, 
in a systematic review, De Wit et al, 2014 summarizes that the chance of carrying a causative 
submicroscopic CNV, when an ultrasound anomaly is present, varies from 3.1 – 7.9 %, 
depending on the anatomical system affected. This increases to 9.1% for fetuses with multiple 
anomalies (31). Oneda et al., 2017 discuss findings showing incremental yields of using CMA 
in fetuses with different types of ultrasound anomalies when karyotype is normal (28). In 
fetuses with congenital heart disease (CHD) with normal karyotype, CMA has shown to yield 
about 7 % additional clinically valuable information (32). As CHD is a common birth defect 
(0.5 – 0.7 %), findings concerning the yield of CMA for this defect is more reliable than less 
common defects. A small cohort comprising only 46 fetuses with CNS anomalies, identified 
pathogenic CNVs in 5 of 46 cases (10.9 %) (33). However, the sample size was relatively small 
and CNS anomalies are a largely heterogeneous group. Thus, additional confirmation in larger 
cohorts are needed to establish rates of incremental yield for CNS anomalies. Vogel et al., 2018 
recently published data showing a significantly higher detection rate using CMA compared to 
karyotyping in a Danish population with increased risk using first trimester screening tests (34). 
Therefore, Denmark also perform prenatal diagnosis on fetuses with high risk estimated by 
screening tests. In summary, the literature seems to support an increased diagnostic yield using 
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CMA in prenatal diagnosis, especially when ultrasound findings are present. However, one 
should carefully consider the type of anomaly found and the relation to the CNV detected. 
1.6 Genetic counselling and ethical considerations in prenatal genomic testing 
The array detects more clinically relevant anomalies including early onset disorders, not 
related to the indication and more genetic anomalies of yet unquantifiable risk, so called 
susceptibility loci (SL) for mainly neurodevelopmental disorders (35). These inconclusive 
findings challenge counselling about risk, clinical significance and possible considerations for 
the pregnant couple. However, by exploring the couple’s desires regarding the level of 
information they want concerning their fetus health, coupled with their practical, medical, 
emotional and ethical views can help aid the parents arrive at a decision that is best suited for 
them. Sometimes this requires several posttest genetic counselling sessions, and may 
challenging due to time constraints. However, the benefits of prenatal genetic testing are 
many. This includes providing reassurance when results are normal, identifying disorders 
where in utero treatment may be needed, and optimizing neonatal outcomes. However, 
prenatal diagnosis also provides the option of pregnancy termination for individual families 
when it is the right choice for them. Consequently, the choice of prenatal testing is up to the 
patient alone with help from the individuals chosen to be included in the decision.  
1.7 Aim of the study 
The purpose of this thesis was to learn about chromosomal microarray (CMA) and its role in 
invasive prenatal testing and evaluate the findings in a selected North Norwegian population, 
all in the light of published studies. In recent years, several papers concerning the developments 
in both non-invasive and invasive testing has been published. Clearly, like other fields of 
medicine, the advances of genomic medicine are impacting prenatal diagnosis,. If the non-
invasive screening test indicate higher risk of trisomy’s or fetal abnormalities, the couple is 
offered invasive diagnostics testing. Until August 2017, conventional karyotyping was the 
choice of invasive diagnostic testing at the Medical Genetic department at University Hospital 




2 Material and Methods  
2.1 Study design and data  
This study is a historical cohort study comparing two group of patients by descriptive data, and 
the genetic findings. The patients in 2016 were offered karyotyping as invasive prenatal testing, 
and the patients in 2017 were offered CMA as invasive testing. Both groups underwent QF-
PCR. Data was gained retrospectively by going through patients’ medical records in 
“distribuent informasjons og Pasientdatasystem i sykehus” (DIPS), biometrics in the service 
application Partus and the lab results in MedGen-datasystem. 
2.2 Karyotyping  
Standard G-band analysis were performed (36). According to the labs routine, 11 cells with 
metaphase chromosomes were analyzed. In cases of suspected mosaicism, 30 cells were 
analyzed.   
2.3 Quantitative fluorescence PCR analysis 
Quantitative fluorescence PCR (QF-PCR) were done using Elucigene kits (37) which consist 
of 22 short tandem repeat (STR) markers for chromosomes X, Y, 13, 18 and 21. The method 
allows for prenatal diagnosis of the most common aneuploidies in a few hours, and is routinely 
used along with CMA or karyotyping techniques. Also, it is inexpensive and one single operator 
may perform up to 40 samples a day (37). The disadvantage is that it may be contaminated with 
maternal cells and therefore be a source of false positive results. Purified DNA from 
amniocentesis or chorionic villous samples were examined by semi-quantitative methods which 
included allele discrimination.  
2.4 CMA analysis 
In Tromsø, the CMA chip used is the Cytoscan HD from Thermo Fisher Scientific (earlier 
Affymetrix). It detects loss or deletions above 30 probes and gain/duplications above 90 probes. 
With the settings of choice (loss 30 probes, gain 90 probes, 5 Mb and 50 SNP markers for areas 
of homozygosity) one may detect unbalanced chromosomal aberrations down to 12 Kb (loss) 
and 36 Kb (gain), and areas of homozygosity larger than 5 Mb. The computer programs used 
in the process of interpretation is Chromosome Analysis Suite (ChAS) from Thermo Fisher 
Scientific and Cartagenia Bench Lab CNV from Agilent Technologies. In Cartegenia, class 3 – 
5 CNV variants are shared with Haukeland University Hospital. 
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2.5 Nomenclature of variants  
For all patients included in the study, variants were described using an international system for 
nomenclature as shown in the guidebook “An International system for Human Cytogenomic 
Nomenclature” (ISCN 2016) (38). If the results of the array are normal the nomenclature for a 
male would be presented as: arr(1-22)x2,(X,Y)x1. There is no space between the “arr” and the 
opening parenthesis, and the sex chromosomes are expressed followed by the autosomes. If the 
array shows an abnormal result one should list only the aberrations. The specific genome built, 
e.g. Genome Reference Consortium (GRCh38) synonymous with hg19, are named in the 
brackets followed by the description of the aberration. The aberration is expressed in the order 
of the chromosome sequence from the lowest to the highest chromosome, regardless of whether 
it is a deletion or duplication. The aberrant nucleotides are written in order from pter to qter. 
One may use commas or underscore between the nucleotides if they are multiple. An example, 
is the partly 7q trisomy we found in one patient named: arr[hg19] 7q11.23q36.3(77,000,129-
159,119,707)x3. This means that the microarray analysis shows a gain in form of three copies 
(shown as x3) in the long arm of chromosome 7 at the bands 7q11.23 trough 7q36.3 in 
molecular position 77,000,129-159,119,707 of chromosome 7. This is a very large duplication 
of 82 120 Kb consisting of 532 genes, and is very rare (table 2). 
2.6 Classifications and interpretation of CMA results  
Abnormal test results are only given to the patients if the CNV findings are related to known 
disease. As much as 12 % of the human genome exhibits CNVs in normal individuals (39). 
Regularly updated online databases catalogue CMA results from normal individuals (39). It is 
not uncommon that a CNV interpretation of clinical significance can be complex. We therefore 
classified CNV findings in different classes (1). Tromsø use three different software programs 
for analysis and registration of findings: Chromosome analysis Suite (ChAS) for molecular 
karyotyping and visualization of findings, MedGen in-house registration system for registration 
of findings and reporting and Cartagenia which contains links to databases of interpretation of 
findings. If there is a CNV finding in class 3 or above, two clinical laboratory geneticists will 
start searching their home database which they share with Haukeland university hospital in 
Bergen. Then they will proceed to investigate the number of genes included in the CNV. If the 
gene in the region is related to disease, known as an Online Mendelian Inheritance in Man 
(OMIM)-morbid gene, it is more likely to be of clinical relevance. Subsequently, the clinical 
laboratory genetics will search the Human Genome Mutation Database Professional (HGMDp) 
for similar findings reported worldwide, and investigate if there are other publications in 
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PubMed, the book “Catalogue of unbalanced chromosome aberrations in man” by Schinzel or 
in other published literature related to the findings (40). The CNV is classified by both of the 
laboratory geneticists independently, before sending it to a medical genetic specialist who will 
conclude by evaluating the classified CNV and the clinical relevance it may hold, and whether 
or not to report the finding. 
2.6.1 Benign and normal results 
Many patients have CNVs that has no clinical consequence. Class 1 and 2 are CNV that are 
benign, and likely benign findings, respectively. Databases of normal variants as (aDGV) aids 
in this process. Benign and likely benign results are given out directly from the bioengineer as 
normal results in MedGen for the medical genetic specialist to convey to the patients in 
consultations.  
2.6.2 Uncertain results 
A class 3 finding is often called a variant of uncertain significance (VOUS). These CNVs can 
be categorized as likely benign (3-) or likely pathogenic (3+). In these cases, parental genetic 
information can be important. The lab always asks for parental genetic samples, but they only 
run the genetic analysis of the parents if there are CNV in class 3-5. This is mostly due to 
economic concerns, as the analysis is expensive and this therefore saves unnecessary costs for 
the laboratory. More importantly, if an apparently healthy parent has the same genotype its 
more likely to be benign. 
2.6.3 Pathogenic results 
CNVs that overlap genes, or larger regions that are known as critical regions of clinical 
significance, are likely to be pathogenic. Class 4 is likely of clinical relevance, and a class 5 
finding is always pathogenic. Class 4 findings may be a CNV within a genotype that is known 
to be related to disease, but the phenotypic expressivity may vary (known as variants of 
vulnerability). An example of a CNV with extreme phenotypic diversity in forms of variable 
expressivity and phenotypic heterogeneity, is 16p11.2 microdeletion. When it comes to class 4 
findings, at least two former patients should have been described with phenotypical features 
that explain the findings in the patient, and the CNV size and placement should be in accordance 
with the cases. When it comes to class 5, the policy is that at least 3 patient cases should be 
described in PubMed with the phenotypical features conformable of the clinical findings, and 




2.7 Population of the study 
Before engaging in the study, the regional committee of medical and health research ethics 
(REK), 2018/1959/REK nord, evaluated the study to be a quality assurance study since this was 
a retrospectively collected sample of data with no new interventions. For the present study, we 
selected all women who had indications for invasive testing in prenatal diagnosis in Northern 
Norway between December 2015 and December 2018. This is a heterogeneous group 
comprising women who were candidates for the first trimester ultrasound because of a high risk 
pregnancy and also patients who were admitted for broad testing due to ultrasound 
abnormalities found in the routine scan in the second trimester. This makes the included sample 
a mix of both high risk patients, and women in the general population with anomalies findings 
on ultrasound discovered on their first routine scan. The sample comprised n=84 women aged 
19 – 45 years (M=33,12, SD=6.6). Between December 2015 and august 2017, invasive tests 
comprised PCR and karyotyping from n=43 women, aged 19 - 44 (M=34.3, SD=6.4). Between 
September 2017 and December 2018, invasive tests comprised PCR and CMA from n=41 
women, aged 19 – 45 years (M=31.8, SD=6.7).   
2.8 Definition of variables 
The definitions of variables in the dataset were determined in cooperation between the student 
and the supervisors prior to the data collection process. We wanted to collect results from both 
the non-invasive and the invasive testing methods. For the purposes of this study, we opted to 
collect as much as possible of the available data materials associated with prenatal testing. This 
included CUB-test results in the high risk pregnancies, structural findings on ultrasound, 
maternal age, QF-PCR results, karyotyping, and CMA results. The definitions of structural 
anomalies on ultrasound included both soft markes, intra uterine growth restriction (IUGR), 
structural anatomical defects, single umbilical artery (SUA), and placenta abnormalities. We 
only collected CMA results from classes 3 through 5, since these would be the CNVs of clinical 
interest. The data was plotted in a spreadsheet format in December 2018 by the student with 
the help from both supervisors.  
2.9 Data analysis 
Findings using karypotyping and CMA were analyzed descriptively and reported casewise in 
separate tables for each group. Within and between-groups results were compared and 
discussed. In addition, total number of reported findings with known clinical relevance was 
compared between groups using a Chi-square test. Between-group differences in demographics 
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(maternal age and gestational age) were compared using independent sample t-tests. 
All statistical analyses were performed using the IBM statistical package for social sciences 
(SPSS) version 25.  
3 Results 
3.1 The Karyotyping group 
In the karyotype group, n=8 (18.6 %) of the fetuses had abnormal findings. All of the abnormal 
karyotypes also had an abnormal QF-PCR test result. In this sample, n=18 (41.8 %) of the 
patients underwent screening with CUB-test (figure 5). None of these patients underwent NIPT, 
as the test was not approved in the time of testing. The mean week of pregnancy when 
ultrasound screening was performed in the karyotyping group was 15.5 weeks, in order of 
biparietal diameter (BPD) measurement. Most of the fetuses in the karyotyping group had a 
normal ultrasound (figure 6). 
Figure 5 KUB-test result in the screening process of the high risk pregnancies in the Karyotyping group. A total of 18 
patients had the KUB-test done. Only one patient had test results for trisomy 21 risk available in the journal. That is why there 
















Figure 6 Ultrasound anomalies in the karyotyping group. 58 % of the fetuses in the karyotyping group had a normal 
ultrasound, while 42 % had ultrasound findings. 
 
3.2 Genetic findings in the karyotype group 
There were two cases of trisomy 21 (T21), three cases of trisomy 13 (T13) and one case of 
trisomy 18 (T18). Also, there were two cases of Turner syndrome: 45, X (table 1). All of the 
aneuploidies detected had abnormal ultrasound findings. Three of the aneuploidies had 
additional genetic chromosomal abnormalities (case 2, 4 and 6 in table 1). One of the T13 had 
a Robertsonian translocation. The T21 had the karyotype: mos 47, XX, + 21 
[18]/48,XX,+10,21[12]. However, the mosaic in this patient seem to complicate the 
chromosomal aberration with a partly trisomy of chromosome 10 in addition to trisomy 21 in 
some of the cultured cells. This was considered to significantly contribute to the health 
aspects of the fetus. However, this fetus had a normal ultrasound scan, apart from the lack of 
nasal bone. Also, one of the fetuses with trisomy 13 had both Patau and Klinefelter syndrome, 
double trisomy, which is extremely rare (41). This fetus presented with the prenatal 




Abnormal ultrasound findings Normal ultrasound
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Table 1 Descriptive findings in the karyotyping group. 
Case Fetal karyotype QF-PCR Ultrasound findings 
Major phenotypic 
features Reporting of finding 




Turner 45, X 
2 46, XX, 
rob(13;14)(q10;q10)+ 13 
Robertian translocation 





and enlargement of 
placenta. 
Patau Syndrome 46,XX, 
rob(13;14)(q10;q10)+ 
13 
3 46, XX, + 21 Trisomy 21 Nuclear Translucency  
> 3.5 mm 
Down Syndrome 46, XX, + 21 







Patau syndrome and 
Klinefelter 
47, XXY, + 13 
 
5 46, XX, + 18 
 
Trisomy 18 Bilateral Plexus choroid 
cysts, VSD, possible 
double kidneys 
Edwars syndrome 46, XX, + 18 
 
6 mos 47, XX, + 21 
[18]/48,XX,+10,21[12] 
Trisomy 21 No nasal bone present Down syndrome 47,XX+21 
7 45, X 45, X Hydrops, nuchal fold,  
left ventricle anomaly. 
Turner 45, X 
8 46, XY, + 13 Trisomy 13 Omfalocele Patau Syndrome 46, XY, + 13 
 
3.3 The CMA group 
Although a total of 15/41 (36 %) patients in the CMA group had first trimester screening in 
weeks 10 – 13 and underwent invasive testing, only 11 of these underwent CUB screening 
(figure 7). While this may be due to missing test results in some of the patient’s medical records, 
one patient had to be excluded because she was carrying twins. None of these patients 
underwent NIPT, as the test was not approved in the time of testing. The mean week of 
pregnancy when ultrasound screening was performed in the CMA group was 16,05 weeks, in 
order of biparietal diameter (BPD) measurement. A total of n=29 (71%) in the CMA group had 
abnormal ultrasound findings (figure 8). While there were no trisomy conditions, one case was 
found with a part aneuploidy on the X chromosome, discovered by QF-PCR. There were n=10 
19 
 
(24.3%) cases with CNVs uncovered (including VOUS). Some of the patients with CNV 
findings had more than one CNV, but these cases were counted in terms of the most severe 
CNV they had. All findings from class 3 – 5 are described in table 2. There were two patients 
(4.8 %) who had a class 4 – 5 CNV (figure 9), and they were therefore classified as pathogenic 
and reported as abnormal results to the parents (table 2).  
 
Figure 7 CUB-test results in the CMA group. Distribution of the adjusted risk of trisomies estimated using the CUB-test in 
screening before invasive testing in the CMA group. A total of 11 of the 41 patients had indication for first trimester screening. 
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Figure 8 Ultrasound anomalies in the CMA group. This may explain why only 36 % of the patients (n=15) in the CMA 
group had a first trimester ultrasound scan from week 10 – 13. Most of the subjects in the CMA group were probably referred 
to invasive diagnostic testing due to structural findings on ultrasound screening during second trimester in relation to the 
national program for antenatal care. 
Figure 9 CNV findings in the CMA group. Portion of CNV findings in the CMA group. 
3.4 Genetic findings in the CMA group 
In total there were 14 CNVs distributed in 10 fetuses. Eleven of them where submicroscopic 
(<10 Mb). Therefore, CNVs were described that would not have been detected by using the 
karyotype method. Eleven of the CNVs were in class 3, classified as VOUS and thus reported 
71 %
29 %




No CNV found or class 1-2 Class 3 Class 4-5
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as normal. One class 4 finding (a 22q11.21 duplication) was reported (case 8, table 2) who also 
had a large class 5 finding. Fetuses with 22q11.21 duplication may be normal, have intellectual 
disabilities, experience developmental delay, growth retardation, or hypotonia. In this case, the 
class 4 finding was clinically subordinate to the class 5 finding, and both were reported to the 
parents. Because of the size of the class 5 CNV (the 7q11.23q36.3 duplication), counting for 82 
Mb, it would also have been detected on karyotyping. It contained as much as 532 genes, and 
73 of them where OMIM-morbid genes. In total there were three class 5 findings in our sample, 
with two of them occurring in the same fetus (case 9, table 2). Both were located on the same 
X chromosome. The largest was a Xp22.33p11.23 deletion, counting for 46.7 Mb, consisting 
of 185 genes, where 44 of them was OMIM-morbid genes. This type of deletion is often 
described in patients with a Turner phenotype. The other was a Xq25q28 duplication, counting 
for 27 Mb, consisting of 210 genes. 49 of these were OMIM-morbid genes, the MECP2 gene 
included. Being situated on the X chromosome, the clinical severity will vary between females 
and males. While females vary in terms of X-inactivation patterns, male fetuses are severely 
affected. Clinical features may include severe developmental disorder (42, 43). Xq28 is a type 
of duplication described in both male and females and may result in Xq28 duplication syndrome 
(44). In this patient QF-PCR was abnormal showing: 46, X, der(X). However, karyotyping was 
also performed in this patient and found to be normal, even though the size of the two class 5 
findings was > 10 Mb.  
3.4.1 Ultrasound findings and CMA test results 
We found that 8 of the 10 patients with CNVs (class 3 – 5) had an ultrasound anomaly. Most 
were not isolated. These anomalies were only related to two of the CNVs found by CMA 
testing. The 7q11.23q36.3 duplication (case 8, table 2) was likely related to the brain and heart 
abnormalities as it has been described in other cases with this duplication (45). Also, the fetus 
had a 22q11.21 duplication which may have contributed to the IUGR. However, the 22q11.21 
duplication has a more uncertain penetrance to phenotype, and the contribution to the IUGR is 












Fetal findings Genomic 
localization (size) 






1 3 Pat 9p13.3 duplication 
(171 Kb) 
 Talipes Normal 
2 3 Mat Xp22.33 duplication 
(871 Kb) 
 Talipes, Eccogenic 
focus in heart 
Normal 
3 3 Pat 16p13.3 duplication 
(182 Kb) 
Intermediate talassemia Acrani Normal 
 3 Mat Xp11.23 duplication 
(118 Kb) 
  Normal 
4 3 Dn 8p23.3p23.2 duplication 
(1443 Kb) 
 Normal Normal 





6 3 Mat 3p26.3 duplication 
(133 Kb) 
VOUS SUA, Pulmonary 
stenosis, Double 
outlet right ventricle 
Normal 
 3 Mat 3q28 deletion 
(8 Kb) 
VOUS  Normal 
7 3 Mat 2q37.1 duplication 
(128 Kb) 
VOUS Talipes Normal 
8 5  7q11.23q36.3 duplication 
(82,2 Mb) 
Heart, brain and kidney anomalies. 
Intellectually; normal to ID. Speech 
problems, hypotonia, seizures, behavioral 
abnormalities, movement and walking 
problems 




 4 Pat 22q11.21 duplication 
(2,5 Mb) 
Growth retardation. Normal to ID or DD. 
Psychomotor developmental-disorder. 
IUGR Abnormal 
 3 Mat 2p16.3 deletion 
(169 Kb) 
 
VOUS  Normal 
9 5 Dn Xp22.33p11.23 deletion 
(46,7 Mb) 
Turner phenotype Normal Abnormal 
 5  Xq25q28 duplication 
(27 Mb) 
Different grades of DD, learning 
difficulties, distinctive facies. 
 Abnormal 
10 3 Mat 16q23.1 duplication 
(1950 Kb) 
VOUS Hydrops Normal 
Note. Abbreviations: ID = Intellectual disability, DD = Developmental delay (1, 44-46) 
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3.5 Comparing demographics and number of findings between groups 
The maternal age in the karyotyping group were slightly higher (M=34.3, SD=6.4), as compared 
to the CMA group (M=31.8, SD=6.7). However, the difference did not reach the threshold of 
statistically significance (t=1.7, p=.09). While no differences in gestational age (as measured in 
weeks) between the karyotyping (M=15.5, SD=3.2) and CMA group (M=15.5, SD=3.2, t=0.7, 
p=n.s.) were demonstrated, some differences between the groups with regards to gestational 
age distributions were observed (figure 10). Although there were no statistically significant 
differences in number of reported findings in the karyotyping group (n=8) compared to the 
CMA group (n=10, χ2 = 2.06, p = n.s.), the small increase in reported findings using CMA may 
suggest a slightly higher detection rate. 
 
Figure 10 Gestational age at diagnosis in the CMA and Karyotyping group. Barchart showing the distributions of 



















4.1 Important findings 
4.1.1 Genetic findings in the karyotyping group and the CMA group 
We found no statistically significant differences in number of aneuploidies in the karyotyping 
group compared to CNVs (in class 3 – 5) in the CMA group. However, when we look at the 
percentage we can see that there are some differences when we use CMA compared to 
karyotyping. The karyotyping group had 18.6% of aneuploidies in their group, all which would 
have been detected with QF-PCR or CMA alone. In contrast, the CMA group had 24.3% 
abnormal findings. That being said, one must be careful in drawing conclusions from these 
results, since the analyzing techniques were not performed in the same group.  
As submicroscopic CNVs are not detectable using karyotyping, we do not know how many 
CNVs could have been detected this group, and CMA analysis may have had added additional 
diagnostic value. Conversely, karyotyping allows for the detection of balanced translocations, 
that may be important regarding to the risk of recurrence, which CMA analysis is not able to 
uncover. If we sort the CNVs (from class 3 – 5) in the CMA group in order of size 11/14 
(78.5%) are submicroscopic (<10Mb). However, only one of the class 5 CNVs (the 
7q11.23q36.3 duplication, case 8, table 2) would have been detected with karyotyping due to 
the size of the duplication; being 82 Mb in size and a partly 7q trisomy. The other two class 5 
CNVs (case 9, table 2) were not detected, even though their size was > 10 Mb. We know this, 
because karyotyping was performed and found to be normal in this fetus. This illustrates the 
limits of karyotyping in terms of being a visual technique. The giemsa stain may be situated in 
an area complicating detection of the chromosome anomaly, or simply bad quality of the 
chromosomes at examination. As both CNVs were located on the same X chromosome this 
may also have made the visualization of the chromosome challenging. If this patient would 
have been tested a year earlier, the class 5 findings would only have been detected as: “46, X, 
der(X)” on QF-PCR, and the genetic counselling may have been different. While this fetus had 
normal ultrasound findings, the indication of prenatal diagnosis was high maternal age. In 
addition to the Xp22.33p11.23 deletion, the Xq25q28 duplication consisted of 210 genes. 49 of 
these were OMIM-morbid genes, and the important MECP2 gene was included. MECP2 is 
associated with the MECP2 duplication syndrome. The clinical characteristics is severe 
neurodevelopmental disorder characterized by several features (infantile hypotonia, delayed 
psychomotor development, progressive spasticity ect.) (42). Severity of phenotypical deficits 
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will vary between males and females. While MECP2 duplication syndrome in males is 100 % 
penetrant, the clinical features in heterozygous females are more challenging to predict. Partly 
due to the course of X-inactivation patterns. As this fetus was female, the prognosis is difficult 
to predict. In contrast, a male fetus with these chromosome anomalies has a poor prognosis (42, 
43). In addition, the Xq28 syndrome is described in both male and females with duplication in 
this area of the X-chromosome (44). However, looking at the overall picture of the descriptive 
findings in this study, all of the abnormal findings in the karyotyping group (except for the 
Robertsonian translocation), would also have been detected using the CMA technique. 
4.1.2 Abnormal copy number variants compared to ultrasound findings  
In several published reports from other cohorts, findings points to an increased detection of 
causative findings using SNP array technology in fetuses with ultrasound abnormalities (14, 
15, 24). In our sample 29/41 (71 %) patients in the CMA group had an ultrasound anomaly, and 
as much as eight of the ten patients with CNVs (class 3 – 5) had ultrasound findings. This 
indicates that CMA is to be the recommended test of invasive testing in pregnancies with 
ultrasound abnormalities (28). Even though we are not able to draw conclusions saying CNVs 
are always related to ultrasound findings, we may argue that a such a finding should warrant 
performing an CMA analysis. Also, this points to the importance of further study of possible 
contributions to phenotypic anomalies, and the importance of publishing findings for improving 
knowledge in the field concerning prenatal phenotypes.  
4.2 Results compared to relevant literature 
As mentioned earlier, prevalence rates of CNV’s and its relation to specific ultrasound 
anomalies vary between studies. Our study employed a relatively small sample size compared 
to larger cohorts (24). Also, it is challenging to compare our results directly to other published 
studies because of the heterogeneous group of individuals in our sample. Partly due to different 
indications for invasive of prenatal testing. We may however compare the fetuses in the CMA 
group with ultrasound finding to some numbers in the literature. For example, in a large cohort, 
Srebniak et al., 2015 showed a detection rate of 4.3 % (44/1033) CNVs explaining the abnormal 
fetal phenotype found on ultrasound (24). Stosic et al., 2018, states that CMA has proven to 
detect CNVs with well-defined clinical significance in up to 6 % in cases with fetal 
abnormalities and a normal karyotype (1). However, in our study we had one 1/29 (3.4 %) fetus 
who had two CNVs that was related to the fetal phenotype, excluding all fetuses with normal 
ultrasound. The incremental yield of using CMA method over karyotyping varies in studies 
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from 1.2 – 2 %, with a incidence for VOUS being 0.3 – 2.7 % when there are no anomalies 
found on ultrasound (1). In our study there was only one CNV of well-defined clinical 
significance (class 4 – 5) that had a normal ultrasound scan. However, the QF-PCR was indeed 
abnormal in this patient (case 9, table 2). We found 11 class 3 findings described as VOUS in 
our sample, only one of these patients had a normal ultrasound. While only 1/29 (3.4 %) of the 
fetuses (case 8, table 2) in the CMA group with ultrasound findings had a submicroscopic CNV 
reported as pathogenic (class 4 – 5), Srebniak et al., 2015 found 57/1033 (5.5 %) 
submicroscopic pathogenic CNVs in fetuses with ultrasound anomalies (24).  
4.3 Benefits and Strengths of the study 
4.3.1 First Norwegian data published  
To our knowledge, no data from the use of CMA in the Norwegian population has been 
published. As CMA now has replaced conventional karyotyping as the standard invasive 
prenatal diagnostic test of choice in Norway, it is important to evaluate if the use of CMA is 
adequate compared to the conventional karyotyping method. This is especially important in the 
process of prenatal diagnosis, where the interpretation and reporting of findings to patients are 
intricate.  
4.3.2 Limited knowledge of prenatal phenotype  
Another important aspect of using CMA is that the more we use CMA SNP technology in 
prenatal diagnosis, the more experience and knowledge will thrive from it. The collection and 
evaluation of data generated from its use, will make diagnosis and prognosis more precise and 
easier to perform in the future. As mentioned earlier, currently we only have ultrasound to 
describe the phenotype in prenatal testing, and most of the phenotypes are described in postnatal 
tested patients/populations. Linking the phenotype to CNV findings is therefore challenging. 
Especially CNV related to neurodevelopmental disorders, since in prenatal setting, we cannot 
determine the neurodevelopmental phenotype, and the same CNV may also appear in 
asymptomatic carriers. Some clinics do not report these types of findings because of this reason. 
Even though there may be structural defects presented we can only by some degree of certainty 
link the findings to the CNV presented by CMA testing. There is still a lot of research that needs 
to be done in this field. Linking the type of ultrasound findings that may occur more frequently 
in fetuses with particular CNVs are important. In Denmark and France they have presented 
some studies who has shown that an increased NT appear in fetuses with CNVs (14, 15). 
Biochemical markers are also important (17). Since there are not many studies describing 
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phenotype links to CNVs, there is a possible bias in over-emphasizing the relevance of findings 
in published literature. Deletion and duplication syndromes that CNV findings can result in are 
mostly rare, which also makes the investigation of VOUS challenging as it requires larger 
datasets to establish potential clinical relevance of the findings. In most cases therefore large 
methodological epidemiological studies are often not possible. However, the descriptive and 
clinical findings offered by this study are of value as it highlights the differences with which 
karyotyping and CMA analysis offer, and it contributes to knowledge of the prenatal 
phenotypical presentation of the CNVs we found.  
4.3.3 Reporting of genetic information 
It has been shown that pregnant couples tend to prefer a maximum of information about the 
health of their unborn child and that parents highly appreciate individualized choices in their 
prenatal testing (28, 35, 46). In our study the termination of pregnancy did not significantly 
increase after CMA testing, which may indicate that ultrasound findings are more important in 
terms of making a decision of termination. Different medical centers have different strategies 
for reporting of CNV findings. In Tromsø, for example, we do not report VOUS found in the 
fetus to the parents. This conservative attitude is shared with the UK, where guidelines 
recommend that VOUS unable to be linked to a potential phenotype should not be reported. 
Australian guidelines highlight the importance of genetic counselling for disclosing abnormal 
VOUS results, and Netherland report all VOUS in genetic counselling. The present paper adds 
to the knowledge of currently available prenatal testing technology, which contribute to the 
goal of giving patients the support and assurance they need to make a choice that is right for 
them and their family. 
4.4 Limitations and weakness of the study 
CMA and karyotyping was not performed in the same group.  Direct comparison of the methods 
was because of this not possible. We opted to compare findings in two independent, but 
demographically similar samples, drawn from a population with clearly defined risk 
parameters. However, chance dissimilarities between our samples may have arisen which could 
have led to biases influencing our results and possible conclusions drawn from them.  For 
example, the span of age is very similar, ranging from 19 – 44 and 19 – 45 but the mean value 
of age in the CMA group is somewhat lower. High maternal age will affect the number of 
finding of aneuploidies in the group of investigation, but not CNV findings. This reflects the 
gestational age of testing as well. A higher age in the mother will result in more pregnancies 
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with indication for first trimester screening. Figure 10 shows the karyotyping group had more 
first trimester ultrasound scans. As earlier mentioned, our study composed of both women with 
an indication of CMA mainly because of high maternal age, while others had an indication due 
to a structural defect in the fetus detected on their first ultrasound. This makes the group 
heterogeneous, and one should therefore be careful to draw any hasty conclusions out of the 
findings comparing the groups. Statistical analysis showed no significant difference in 
gestational age between the groups. The gestational age does not affect the invasive test result, 
but may matter when comparing number of findings between the groups. Here, the slightly 
higher age may explain why there are more aneuploidies in the karyotyping group. If there are 
more high risk pregnancies in the karyotyping group, there will be a higher probability of 
aneuploidies detected. While the ideal study design may have been to perform both karyotyping 
and CMA in the same group for comparison. To run both tests would have cost the lab extra 
money, and would have made the planning of the study more intricate. 
4.5 Future perspectives of prenatal diagnosis 
In retrospect of this thesis one should consider establishing a national collection of data 
concerning prenatal diagnosis in the Norwegian population. By collecting data of biochemical 
serum markers, phenotypical findings, and molecular genetic findings, this would contribute to 
the field of prenatal diagnosis. Also, following the fetuses prospectively from described 
prenatal phenotypical features, to postnatal, and neonatal settings may be of great clinical value. 
In the future one may also see prenatal diagnosis evolve in concern of being more accurate in 
the purpose of investigation. Different techniques used for genomic testing, like WES, may also 
be achievable in dedicated laboratories with the intention to investigate specific exons known 
to cause genetic disorders. Sanders and collages has performed WES in a neonatal setting where 
rapid diagnosis was performed in neonatal units (47). While these methods may contribute to 
customize the etiology of ultrasound findings, it may also help evolve the field of medical 
genetics. However, this is a medical field in great development and as we learn to understand, 
more data is needed to secure our knowledge.  
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5 Conclusion 
The purpose of this thesis was to learn about chromosomal microarray (CMA) and its role in 
invasive prenatal testing, and evaluate the findings, as it recently replaced the karyotyping 
method. Using CMA, we discovered 14 CNVs distributed in 10 fetuses. As our reporting policy 
is conservative, only the CNVs of certain clinical importance was reported to the parents, and 
four CNVs were reported. As CMA was recently introduced to prenatal diagnosis in Norway, 
the evaluation of its use through the first year in Tromsø was of important value, but more study 
is needed. Thus, one should consider establishing a national cohort to evaluate the use of CMA 
in prenatal diagnosis in the Norwegian population. 
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Median maternell alder 35.9 (18-46) 
67.6% av fostrene som hadde T21 hadde en mor over 35 år. 


















26.5% av fostrene som hadde T21 hadde NT over 3.1 
mm hvis PAPP-A Mom var i området 0.001-0.500 
(52.94%) 
Sjekkliste:  
Er formålet klart formulert? 
Foreligger det seleksjonsbias?  
Er det tatt hensyn til bakgrunnsfaktorer? 
Var de eksponerte individene representative for 
en definert befolkningsgruppe/populasjon?  
Er den som vurderte resultatet blindet for 
gruppetilhørighet?  
Var studien prospektiv? Ja. 
Ble mange nok personer i kohorten fulgt opp? 
Er det fullført frafallsanalyser?  
Var oppfølgningstiden lang nok til å påvise 
positive/negative utfall? Ja. 
Er det tatt hensyn til viktige konfunderende 
faktorer? Ikke tatt hensyn til: næring i 
svangerskapet, uoppdagede mutasjoner, 
polymorfisme og miljøfaktorer.  
Tror du på resultatene?  
Kan resultatene overføres til den generelle 
befolkningen?  
Annen litteratur som styrker eller svekker 
resultatene?  
Hva betyr resultatene for endring av praksis? 
Styrke 
 Bare 251 foster er undersøkt





PAPP-A og β-hCG 
verdier oppgitt i 
MoM viste ingen 
korrelasjon med 











Referanse:     
Srebniak MI, Diderich KEM, Joosten M, et al. Prenatal SNP array testing in 1000 fetuses with ultrasound anomalies: causative, unexpected 
and susceptibility CNVs. European Journal Of Human Genetics. 2015;24:645. 
Design: Kohort 
Dokumentasjonsnivå 
Grade:   Moderat 
Formål Materiale og metode Resultater Diskusjon/kommentarer 
Evaluere diagnostisk 
verdi av SNP array 
analyse av foster som 
har ultralydfunn, samt 
undersøke prevalens 
og den genetiske 
naturen av de 
patogene funnene man 
fant. 
Populasjon: 
N = 1033 
Alle foster med ultralydfunn ble 
inkludert for CMA analyse: 
Myke markører, IUGR, 
polyhydramnios, strukturelle 
misdannelser, NT ≥ 3.5 mm. og de 
med IUFD (med eller uten 
ultralydfunn) 
Eksklusjon: 












d. Insident funn (IF)




Alle er funn er kjørt på samme 




Til sammen 76/1099 (7.4%) patogene funn 
 Mikroskopiske patogene 19/1033 (1.8%)
 Submikroskopiske patogene 57/1033 (5.5 %)
Array klassifisering av de patogene funn 
 CAU (58%) n = 44
31 av 44 ved kausative funn var de novo, 13 var nedarvet.
 SL (35%) n = 27
6 var de novo og 13 var arvet fra tilsynelatende frisk forelder
 UD (6%) n = 5
Alle var de novo
58% (44/76) av CAU hadde en fenotype som samsvarte med 
arrayfunnet. 
25% hadde blitt funnet ved bruk av karyotypering 
75% kunne kun finnes ved bruk av CMA 
Det ble funnet en signifikant høyere insident av SL hos foster med 
ultralydfunn, kontra de uten ultralydfunn. 2.6% (27/1033) versus 
1.35% (18/1033), Odds ratio 1.056 med 95% KI 1.071, 3.572, P 
=0.01951. (Fisher exact) 
Sjekkliste:  
Er formålet klart formulert? 
Ja, men kunne vært mer spisset. 
Foreligger det seleksjonsbias? Kunne ha oppgitt 
distribusjon av feks maternell alder, hvor mange 
ultralydundersøkelser, gj.snittlig gestasjonsalder 
osv. 
Er det tatt hensyn til bakgrunnsfaktorer? 
Aneuploidier er ekskludert 
Var de eksponerte individene representative for 
en definert befolkningsgruppe/populasjon? 
foster m/ ultralydfunn uten aneuploidier hos foster 
Er den som vurderte resultatet blindet for 
gruppetilhørighet? Usikkert. 
Var studien prospektiv? Ja. 
Ble mange nok personer i kohorten fulgt opp? 
Ja.  
Er det fullført frafallsanalyser? Usikkert. 
Var oppfølgningstiden lang nok til å påvise 
positive/negative utfall? Ja. 
Er det tatt hensyn til viktige konfunderende 
faktorer? Ikke tatt hensyn til: næring i 
svangerskapet, uoppdagede mutasjoner, 
polymorfisme og miljøfaktorer.  
Tror du på resultatene? Ja. 
Kan resultatene overføres til den generelle 
befolkningen? Til gravide med ultralydfunn uten 
andre spesifikasjoner. 
Annen litteratur som styrker eller svekker 
resultatene? Styrker. 
Hva betyr resultatene for endring av praksis? At 
CMA er en god analyse for foster med ultralydfunn. 
At man vil få en del uventede funn når man gjør 
prenatal genomisk testing. 
Styrke 
 Høyt ant foster er med i studien, over 1000
 Viser ratio mellom kausative og uventede funn
 Alle er testet og tolket på samme senter
Svakhet 
 Veldig mange ulike grupper av fenotyper er
inkludert. Gir oss kun generell info.
 Lite maternell informasjon
Konklusjon 
CMA burde benyttes for å 
undersøke for kromosom 
aberrasjoner med 
kausativ karakter hos 
foster hvor det foreligger 
ultralyd funn. 
I tillegg ble det påvist 
uforutsette funn som kan 
være fordelaktig for 
pasienten å ha kunnskap 
om. 
SL opptrådde oftere hos 
foster uten ultalydfunn, 
enn de med ultralydfunn. 





År data innsamling 
2009-2013 
31 
Referanse:     
Egloff M, Hervé B, Quibel T, Jaillard S, Le Bouar G, Uguen K, et al. Diagnostic yield of chromosomal microarray analysis in fetuses with isolated 
increased nuchal translucency: a French multicenter study. Ultrasound in Obstetrics & Gynecology. 2018;52(6):715-21. 
Design: Historisk Kohort 
Grade:   Moderat 






CMA i en 
populasjon av 
foster med økt 
med NT ≥ 3.5 
mm. 
Populasjon: 
720 foster med isolert NT ≥ 3.5 mm målt i 
gestasjonsalder uke 10 til 13+6 
Eksklusjon: 
 Foster med andre UL funn.
 De med aneuploidier funnet vha
hurtigtester
 De med aneuploidier påvist av hurtigtester
som PCR (121 stk av de 720 (16.8%))
Metode 
 Prøvematerialet: AF(78%) og CVS (22%)
 Hurtigtester: MLPA, BoBs, PCR, eller direct
CVS preparation avhengig av sentre.
 Blood-stained AF prøver ble i tillegg dyrket.
 Resultat av CMA ble tolket «på nytt» i
retrospekt av to medisinske cytogenetikere.
 Det ble brukt offentlige databaser og
publisert litteratur for å fasilitere tolkningen.
 Når det ikke ble gjort konvensjonell
karyotypering i tillegg, ble det antatt at de
over 10 Mb var synlig.
 Ved mistanke om placental mosaicisme ble
det gjort karyotyping og/eller CMA fra
dyrkede CVS og AF.







5. CNV ikke relatert til fenotype
599 stk gjennomgikk CMA analyse 
Median maternell alder hos de 599 var 31 år (14-45). 
Median gestasjons alder var 13 uker. Median NT tykkelse var 4.3 mm. 
53/599 (8.8%) hadde kopitallsfunn 
Av disse 53 var  
1) 21/53 (3.5%) Benigne
2) 8/53 (1.3%) VOUS
3) 16/53 (2.7%) Patogen
7/53 korresponderte til genetiske tilstander med variabel penetrans og ekspressivitet. 
1/53 insident funn 
6 av CNVene korresponderte med kjente syndromer. Kun et av disse relatert til 
DiGeorge syndrom. 
Distribusjon av ulike former for CNV relatert til NT tykkelse: 
Vi ser at deteksjonsraten av patogene/kryptiske CNV korrelerer med verdien av 
NT målet. 
- Av de svangerskapene hvor man fant patogene CNVs valgte 12/16 (75%) 
kvinner å terminere svangerskapet. 
- Av de 8 hvor man fant VUS valgte 3/8 (38%) å terminere svangerskapet. 
- Av de 7 med predisposisjon til neurodevelopmental disorders valgte 3/7 
(43%) å terminere svangerskapet. 
I denne studien ble det funnet at de relevante CNV kunne vise til en et diagnostisk 
utbytte på kun 2.7% som er lavere enn 4% som er funnet i artikkelen Grande, et 
al.2015, 
de Wit et al. reported that the rate of cryptic CNVs can reach 7% when increased NT is 
associated with at least one other ultrasound finding.  
Det er altså forskjeller I studier. 
Sjekkliste:  
Var gruppene sammenliknbare i forhold til 
viktige bakgrunnsfaktorer? Vanskelig å svare 
på. Vi vet ikke enda nok om hva som gir 
nakkeoppklaring. Høy maternell alder? 
Teratogener? Miljø i uterus? Se eksl krit. Ifht 
hva man har antatt vil påvirke resultatet. 
Er gruppene rekruttert fra samme 
populasjon/befolkningsgruppe? Ja. 
Var de eksponerte individene representative 
for en definert 
befolkningsgruppe/populasjon? 
Representativt for foster med økt NT. Median 
maternell alder oppgitt og median tykkelse på 
NT hvor det ikke foreligger aneuploydi. 
Var studien prospektiv? Nei, retrospektiv. 
Ble eksposisjon og utfall målt likt og pålitelig i 
de to gruppene? En gruppe. 
Ble mange nok personer i kohorten fulgt opp? 
Godt ant. 720. 
Var oppfølgingstiden lang nok til å påvise 
positive og/eller negative utfall? Ja 
Er det tatt hensyn til viktige konfunderende 
faktorer i design/gjennomføring? 
Eksklusjonskr. Ja. 
Er den som vurderte resultatene 
(endepunktene) blindet gruppetilhørighet? En 
gruppe. 
Styrke 
 Høyt antall foster innen gitte kriterier
 Man har ekskludert andre tilstander
som kan gi NT hos et foster
 Retrospektiv analysering av resultater
av CMA i tillegg til opprinnelig
analysering som var foretatt i klinikken
Svakhet 
 Ulike CMA maskiner er benyttet.
 Gjengir ikke tydelig samme kategorier i
resultater som i metodedel.
 Oppgir ikke hvordan de regner ut KI
Konklusjon 
CMA kan være en 
fordel å benytte når 
man søker årsaks 
diagnose hos foster 
med en isolert økt NT 
Funn viser 2% har en 
cryptic patogen CNV. 
I tillegg fant man 
genomic imbalances 










Referanse:     
Vogel I, Petersen OB, Christensen R, Hyett J, Lou S, Vestergaard EM. Chromosomal microarray as a primary diagnostic genomic tool for 
pregnancies defined as being at increased risk within a population based combined first-trimester screening program. Ultrasound in 
Obstetrics & Gynecology.n/a-n/a. 
Design: Historisk Kohort 
Grade - kvalitet   Moderat 
Formål Materiale og metode Resultater Diskusjon/kommentarer/sjekkliste 
Å evaluere bruk av CMA 
som diagnostisk test i 
undersøkelse av 
genetiske aberrasjoner  
hos foster hvor det 
foreligger økt risiko ved 
første trimester screening 
(cFTS) ≥ 1:300 
Studiepopulasjon: N = 575  
svangerskap med forhøyet combined 
first-trimester screeningtest (cFTS) for 
aneuploidier i gestasjonsuke 8-20 uke 
og dermed vedgikk invasiv testing med 
CVS og amniocentese. 
Alle med forhøyet risiko (≥ 1:300 for 
T21, ≥150 for 18/13) etter screeningtest 
basert på: maternell alder, Nuchal 
Translucecy (NT) tykkelse, og maternelt 
serum proteinene PAPP-A og -HCG i 
kombinasjon. Samt andre trimester 
ultralyd screening ved uke 18-20 
gestasjonsalder. 
Eksklusjon: 
Indikasjoner for invasiv testing som 
følge av   
- NT > 3.5 mm 
- NIPT 
- IUGR 
- Kjent CNV 
Disse ble ekskludert fordi de allerede 
har vist å medvirke til en høyere 
deteksjonsrate ved bruk av CMA. 
CMA Matrise 
Alle CMA analyser ble gjort med CGH 
microarray 180K. Funn av CNV ble 
kategorisert i tre grupper: benign, 
patogen, eller VOUS. En subgruppe 
patogene CNV ble navngitt 
susceptibility variant. 
561 stk. hadde en CVS, resten hadde 
fostervannsprøve. 
Statistisk analyse  
McNemar two tailed test Chi-square and 
McNemar two-tailed tests were usedfor 
statistical analysis and http://vassarstats.net/ 
was usedfor the calculation of CIs 
 
Median maternell alder var 33 år (21-47). 
Fordeling av risiko i studiepopulasjonen: 
139 stk (24%) av svangerskapene hadde risiko estimert til >1:50 
135 stk (24%) –”— mellom 1:50 og 1:99 
301 stk (52%) ---”--- mellom 1:100 og 1:300. 
Patogene funn i 51/575 (8.9%) 
22/575 trisomier (21, 18 og 13), 
6/575 (1%) X aneuploidi  
8/575  andre former for aneuploidi (1.4%). 
15 CNV av sannsynlig patogen og patogen variant ble funnet. 
3/15 CNV var > 10 Mb og hadde vært mulig å se på karyotypering 
12/15 CNV var < 10 Mb og kun synlig på CMA 
8.9% (95% CI, 6.8-11.5%) var sig høyere enn karyotyp 6.8% (95% CI, 5.0-
9.1%)(P=0.0049). 
Deteksjonsraten for CMA samlet sett var signifikant høyere hvor 
51/575 (8.9%), sammenliknet med estimerte funn av tradisjonelle 
cytogenetiske analyser hvor bare 39/575 (6.8%) hadde blitt oppdaget. 
(McNemar two tailed test). 
Hvis man slår sammen de to risikogruppene med minst risiko (altså fra 1:50-
1:300) vil det bli 28 oppdagede patogene tilfeller. Av disse 28 ville kun 4 blitt 
fanget opp vha. NIPT som fokuserer på kromosom 21, 18 og 13. 
Sjekkliste:  
Er formålet klart formulert? Ja 
Er gruppene rekruttert fra samme 
populasjon/befolkningsgruppe? (seleksjonsbias) 
Samme gruppe. 
Var gruppene sammenliknbare i forhold til viktige 
bakgrunnsfaktorer? Ja, fordi det er undersøkt i samme 
populasjon. 
Var de eksponerte individene representative for en 
definert befolkningsgruppe/populasjon? Ja 
Ble eksposisjon og utfall målt likt og pålitelig (validert) i 
de to gruppene? (classification bias) Ikke relevant. 
Er den som vurderte resultatene (endepunkt-ene) 
blindet for gruppetilhørighet? Ukjent. 
Var studien prospektiv? Nei. 
Ble mange nok personen i kohorten fulgt opp? Ja. 
Er det utført frafallsanalyser? Nei.  
Var oppfølgingstiden lang nok til å kunne påvise 
positive eller negative utfall? Ja. 
Er det tatt hensyn til viktige konfunderende faktorer i 
design/gjennomføring av analyser? Ja. Man har 
ekskludert viktige kjente konfunderende faktorer som 
NT ≥ 3.5, IUGR . 
Tror du på resultatene? Ja. 
Kan resultatene overføres til den generelle 
befolkningen? Nei, dette er en selektert 
høyrisikogruppe. 
Annen litteratur som styrker/svekker resultatene? 
Hva betyr resultatene for endring av praksis? 
At man ved å kategorisere risikogrupper ved bruk av 
screeningtesten må være forsiktig. Lavere risiko på 
screeningtestene utelukker ikke kopitalsfunn. NIPT burde 
ikke benyttes som diagnostisk test, da CMA i mye større 
grad er sensitiv for funn. 
Ble eksposisjon og utfall målt likt og pålitelig i de to 
gruppene?  
Alle CMA analyser ble utført av en SurePrint G3 Human 
CGH microarray 180 K 
Styrke  
Noen senter tilbyr NIPT istedenfor karyotypering til 
kvinner med en cFTS risiko mellom 1:50-1:000. Hvis en 
slik gruppestrategi hadde blitt gjort her til 
sammenlikning, ville hele 24 av de 51 abnormale 
resultatene blitt oversett. 
Svakhet cFTS er designet til å oppdage trisomi 21, 18 og 
13 – ikke generelle genomiske aberrasjoner. 
Konfunderende faktorer som teratogener/eksposisjoner 
Konklusjon 
CMA kan identifisere flere 
genomiske aberrasjoner i 
svangerskap med økt 
risiko definert fra cFTS.  
Dersom man kun bruker 
CMA i de gruppene med 
høy risiko (1:100 eller 
1:50), slik det er foreslått i 
modeller med 
gruppestrategi, til bruk av 
NIPT hos de > 1:50, så vil 
det føre til at en signifikant 
proporsjon av patogene 
CNV ikke blir oppdaget 
ved screening i første 
trimester. Dette fordi også 
mange blir fanget opp i 








Referanse:     
Lund IC, Christensen R, Petersen OB, Vogel I, Vestergaard EM. Chromosomal microarray in fetuses with increased nuchal translucency. 




Grade:   Lav 
Formål Materiale og metode Resultater Diskusjon/kommentarer 
Å vurdere klinisk 
nytteverdi av å benytte 
CMA i prenatal 
diagnostikk av foster med 
økt nakkefold. Dette i en 
populasjon hvor 
individene ble screenet 
med screeningverktøy 
designet for å oppdage  
T21 i første trimester hvor 
bla NT-mål inngår. 
Populasjon: 
136 foster med NT mål ≥ 3.5 mm. Første 
trimester (11-13 uke). 
95% gjennomgikk screeningtester 
Eksklusjon: 
4 tilfeller ble ekskludert da det forelå flere 
UL anomalier enn NT: 
 myelomeningocele (n=1)
 omphalocele + talipes (n=1)
 talipes (n= 1)
 kardiell arrytmi + hydrops (n=1)




 PCR av alle (n = 132)
 Karyotypering av alle abnormale
PCR (n = 38)
 CMA av alle normale PCR (n =
94)
CMA: 
SurePrint G3 Human CGH microarray 






Statistisk analyse  
Utført vha GraphPad Prism, versjon 4.03.  
Mann-Whitney U-test for å undersøke 
forskjeller mellom gruppene. 
Chi-square test for å teste for sig. Forskjell 
i forventet frekvens. 
P<0.05 ble vurdert statistisk signifikant i en 
two-sided test.  
Viktige konfunderende faktorer 
Foreldreprøver ble kjørt dersom det forelå 
VOUS hos foster. 
Hovedfunn 
N = 132. Maternell alder varierte mellom 18-43. Median alder var 
31. Median NT mål var 4.2 (3.5-13.8 mm). 96.2% hadde isolert
NT. 3.8% hadde føtal hydrops i tillegg til økt nakkefold. 
Karyotypering 
 38/132 (28.8%; KI 21.8-37.0%) hadde vanlige





o 2/38 annen tripoidi
CMA 
 15/94 (16%; 95% KI 9.9-24.7%) som utførte CMA analyse
hadde kopitallsfunn i form av VOUS eller patogen
klassifikasjon. 11/15 var submikroskopiske og hadde ikke
blitt sett på karyotypering.
o Benign 5/94
o VOUS 3/94 (3.2%;95% KI, 1.1-9.0%)
o Patogene: 12/94 (12.8%; 95% KI, 7.5-21%)
 Median alder hos mødrene med de
patogene variantene av CMA funn var 30
år (21 - 35 år).
NT størrelse 
 75/132 (57.6%) var NT 3.5-4.4 mm. I de resterende 56
casene var NT > 4.5mm.
 De høyeste NT verdiene var målt hos de fostrene som
hadde anormale funn på QF-PCR og CMA
o Abnormale QF-PCR: aneuploidier (n=38) hadde
median NT: 4.8 mm vs. 4.1 mm hos de med
normal QF-PCR (n = 94), P = 0.01.
o Abnormale CMA (n=15). Her hadde 9/15 NT mål
over 4.5 mm
Sjekkliste: 
• Var formålet klart formulert? Ja
• Var studien basert på et tilfeldig utvalg
fra en egnet pasientgruppe?
(seleksjonsbias) Ja.
• Var inklusjonskriteriene klart definert?
Ja
• Var alle pasientene i samme stadium
av sykdommen? Ja. Alle er i første
trimester.
• Er svarprosenten høy nok?
(frafallsanalyser) Noe lavt ant.
• Ble objektive kriterier benyttet for å
vurdere/validere endepunktene?
(classfic bias)
• Ved sammenlikninger av pasientserier,
er seriene tilstrekkelig beskrevet? Ja
• Er prognostiske/konfunderende
faktorers beskrevet/tatt hensyn til i
design og analyse? Alle burde hatt
isolert NT
• Var registreringen av data prospektiv?
Ja.
• Var oppfølgningen lang nok? Ja
• Var oppfølgningen tilstrekkelig for å nå
endepunktene?  Ja
• Stoler du på resultatene? Ja
• Kan resultatene overføres til praksis?
Ja.
• Annen litteratur som støtter
resultatene? Ja
Styrke 
Viser at det er nyttig å gjøre CMA hos foster 
med NT over 3.5 mm og at karyotypering ikke 
er tilstrekkelig alene. 
Svakhet 
Lavt ant foster. 
Konklusjon 
CMA er en verdifull 
diagnostisk teknikk i 
svangerskap med isolert 
føtal NT ≥ 3.5mm. 
Deteksjonsrate på 12.8% 
hos de med NT ≥ 3.5mm, 
mens det i gruppen med 
NT ≥ 4.5mm viste en 




År data innsamling 
Januar 2013 til Juli 
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